Physician profile
Casey C Geringer
NPI 1871702654
$3,831.24
in general payments reported to CMS, 2019-2025
23 companies · $925 in 2025
The $925 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $207 · 2021: $341 · 2022: $567 · 2023: $831 · 2024: $839 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Entertainment: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.03 |
| Entertainment | $144.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.12 | 2022-2025 | |
| Alcon Vision LLC | $745.98 | 2021-2025 | Lensx, Rocklatan, Tryptyr |
| Sight Sciences, INC. | $345.93 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $325.86 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $181.43 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $178.20 | 2022-2025 | Vyzulta, Lotemax Sm, Prolensa |
| Glaukos Corporation | $177.53 | 2021-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Nova Eye, INC. | $144.54 | 2025 | |
| Sun Pharmaceutical Industries INC. | $139.47 | 2020-2024 | Cequa |
| Thea Pharma INC. | $112.59 | 2022-2024 | Iyuzeh |
| Harrow Eye, LLC | $88.77 | 2024-2025 | Vevye |
| New World Medical,INC. | $75.52 | 2022-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Ocular Therapeutix, INC. | $73.00 | 2019-2024 | Dextenza |
| Medtronic, INC. | $69.33 | 2021 | |
| Oyster Point Pharma, INC. | $56.51 | 2023-2024 | Tyrvaya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.76 | 2019-2020 | |
| Akorn Operating Company LLC | $48.84 | 2021 | |
| Kala Pharmaceuticals, INC. | $44.55 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $30.65 | 2022 | |
| Aerie Pharmaceuticals, INC. | $24.76 | 2019 | |
| Ani Pharmaceuticals, INC. | $19.87 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $14.29 | 2024 | Tepezza |
| Omeros Corporation | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Geringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.